Showing 167 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

U.S. Clinical Trials Begin for Twice-Yearly HIV Prevention Injection

Editor's pick
National Institute of Allergy and Infectious Diseases
4 June 2024

UK: New cabotegravir formulations approved to help prevent HIV-1 infection in adults and adolescents

Editor's pick
Medicines and Healthcare products Regulatory Agency (MHRA)
6 May 2024

Long-Acting PrEP in Europe's Fight Against HIV

Editor's pick
Medscape (requires free registration)
1 December 2023